GGrantIndex
Sort

50,496 grants matching lung cancer

Therapy for Metastatic breast cancer based on micro RNA silencing

$572,534
Zdravka O. Medarova · Massachusetts General Hospital · R01 · FY2018 · CA

Mouse Models of Metastatic Triple-Negative Breast Cancer for Therapeutic Testing

$572,521
Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2016 · CA

Predictive biomarker of BET bromodomain inhibitor in Small cell lung cancer

$572,509
Haobin Chen · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Developing an Effective BET bromodomain inhibitor Drug Combo to Target SCLC

$572,509
Haobin Chen · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Separation and Analytical Technologies for Proteomics

$572,496
Barry L. Karger · Northeastern University · R01 · FY2010 · GM

Integrative molecular and imaging approaches for risk of subtype specific breast

$572,435
Randa A El-Zein · Methodist Hospital Research Institute · U01 · FY2017 · CA

Proteomics Biomarkers Development Laboratory

$572,408
Samir M Hanash · Fred Hutchinson Cancer Research Center · U01 · FY2007 · CA

Early Detection of Ovarian Cancer Through Epigenetic Factors in the WHI

$572,330
Jeanine M. Genkinger · Columbia University Health Sciences · R01 · FY2017 · CA

Development of chemical probe targeting NSD3 SET domain in breast cancer

$572,327
Tomasz Cierpicki · University Of Michigan At Ann Arbor · R01 · FY2025 · CA

Development of chemical probe targeting NSD3 SET domain in breast cancer

$572,327
Tomasz Cierpicki · University Of Michigan At Ann Arbor · R01 · FY2024 · CA

Ultrasensitive Detection of Tumor Specific DNA Methylation Changes for the Early Detection of Lung CancerÂ

$572,321
James G. Herman · University Of Pittsburgh At Pittsburgh · U01 · FY2020 · CA

Targeting Tumors with NF1 Loss

$572,285
Yolanda Sanchez · Dartmouth College · R01 · FY2015 · NS

Development of 3D Alveolar Tissue Models, CRISPR-editing and Microbiota-immune Response Assay Platforms for Deciphering Human Lung Immunity

$572,263
Derya Unutmaz · Jackson Laboratory · U19 · FY2021 · AI

Immunotherapeutic responses to neoantigens in head and neck cancer

$572,257
Ravindra Uppaluri · Dana-Farber Cancer Inst · R01 · FY2022 · DE

Primary screening and hit follow up to identify the first selective inhibitors of PLC?1 and PLC?2

$572,254
Zhong-Yin Zhang · Purdue University · R01 · FY2025 · CA

Discovery of Small Molecule Ligands for PHD1 Reader Domain of Histone Demethylase KDM5A

$572,202
Danica Galonic Fujimori · University Of California, San Francisco · R01 · FY2022 · CA

Discovery of Small Molecule Ligands for PHD1 Reader Domain of Histone Demethylase KDM5A

$572,202
Danica Galonic Fujimori · University Of California, San Francisco · R01 · FY2023 · CA

Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer

$572,168
Dan R Littman · New York University School Of Medicine · R01 · FY2025 · CA

Mechanism of microbiota-mediated potentiation of checkpoint blockade efficacy in lung cancer

$572,168
Dan R Littman · New York University School Of Medicine · R01 · FY2021 · CA

Single-cell atlas of lung tissue-resident memory T cells reactive to upper and lower respiratory tract pathogens

$572,159
Pandurangan Vijayanand · La Jolla Institute For Immunology · U19 · FY2024 · AI

The connection of innate and adaptive anti-cancer immunity

$572,121
John Greiner · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

The use of chitosan for cancer vaccine delivery

$572,121
John Greiner · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

HTS for TGF-beta receptor assembly inhibitors with anti-tumor and anti-fibrosis activities

$572,036
Andrew P Hinck · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · CA

Precision Lung Cancer Survivorship Care Intervention: A Randomized Controlled Trial Serving Rural Survivors and Communities

$571,997
Jamie L Studts · University Of Colorado Denver · R01 · FY2024 · CA

Tumor stem cells and metastatic outcomes in mouse models of prostate cancer

$571,994
Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA